January 20, 2021

On January 19, biopharmaceutical company Theratechnologies Inc. closed its bought-deal public offering of units of the company, including the full exercise of the over-allotment option, for aggregate gross proceeds of more than $46 million. The company plans to use the net proceeds of the offering to fund research and development activities, commercialization initiatives, general and administrative expenses, working capital needs, and other general corporate purposes. Led by Partner Martin C. Glass, the team included Partners Geoffrey M. Davis and Louis E. Fogel and Associate Kristen M. Iglesias.